KRAS and acute myeloid leukemia: From a therapeutic perspective, previous studies focusing on KRAS mutant colorectal cancer and acute myeloid leukemia have indicated that the WT copy of the KRAS gene is associated with resistance to treatment with MEK inhibition [17,18].